MORPHINE SULFATE INJECTION USP SOLUTION

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

MORPHINE SULFATE

Beszerezhető a:

PFIZER CANADA ULC

ATC-kód:

N02AA01

INN (nemzetközi neve):

MORPHINE

Adagolás:

2MG

Gyógyszerészeti forma:

SOLUTION

Összetétel:

MORPHINE SULFATE 2MG

Az alkalmazás módja:

INTRAMUSCULAR

db csomag:

10X1 ML

Recept típusa:

Narcotic (CDSA I)

Terápiás terület:

OPIATE AGONISTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0104545008; AHFS:

Engedélyezési státusz:

CANCELLED PRE MARKET

Engedély dátuma:

2019-03-04

Termékjellemzők

_ _
_Product Monograph - _
_N_
_MORPHINE SULFATE INJECTION USP _
_Page 1 of 33 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
MORPHINE SULFATE INJECTION USP
Sterile Solution
2 mg/mL, 10 mg/mL and 15 mg/mL
Narcotic Analgesic
Pfizer Canada Inc
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of Revision:
October 3, 2018
Submission Control No: 219782
_ _
_Product Monograph - _
_N_
_MORPHINE SULFATE INJECTION USP _
_Page 2 of 33 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................22
SPECIAL HANDLING INSTRUCTIONS
.......................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
................................................................................24
PHARMACEUTICAL INFORMATION
...................